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Chronic kidney disease (CKD) patients are prone to a
higher cardiovascular morbidity and mortality compared
with the general population [1]. Consistent results from
the basic and clinical research showed that cardiovascular
susceptibility in CKD is due, partially at least, to a consider-
able acceleration of the vascular ageing processes in the
context of chronic kidney disease-mineral bone disorder
syndrome (CKD-MBD) [2]. This premature cardiovascular
senescence is mainly characterized by altered endothelial
reactivity, followed by pathologic calciﬁcation of cardiac
valves and medial layer in the arteries [3]. The consequent
increase of arterial stiffness worsens the cardiac afterload,
contributing to the onset of left ventricular hypertrophy
and to the progressive increase of pulse pressure (PP)
leading to a signiﬁcant reduction of diastolic tissue per-
fusion. The metabolic pathways linked to this premature
ageing involve the dysregulation of several systems such
as inﬂammation, oxydative stress, insulin resistance and
mineral metabolism [3]. The alterations of calcium (Ca)
and phosphate (P) homeostasis in renal patients, mainly
driven by a derangement of Klotho/ﬁbroblast growth
factor 23 (FGF23)—parathormone (PTH)—vitamin D axis,
are considered pivotal triggers and regulators of vascular
ageing rather than mere biomarkers of CKD-MBD syn-
drome [3]. Thus, P overload and hyperparathyroidism are
well known targets of medical treatments, such as P
binders, vitamin D and calcimimetics, although with still
limited evidence-based advantages in terms of survival in
renal patients [3, 4]. The tough hedge that is still keeping
nephrologists far from a conclusive and winning approach
against vascular ageing is reasonably related to the still
partial comprehension of the molecular pathways in-
volved in a so complex, multifactorial and extreme
process. New biomarkers and new actors are thus needed
to orient the scientiﬁc knowledge towards further inter-
vention strategies against CKD-MBD.
In the present issue of the Clinical Kidney Journal,
Fragoso et al. [5] present the ﬁrst observational data
linking magnesium (Mg) and FGF23 levels to PP in 80
pre-dialysis type 2 CKD diabetic patients. This elegant
cross-sectional analysis observed that a PP higher than
50 mmHg was independently associated with lower Mg
and higher FGF23 levels [OR 0.550 (95% CI 0.305–0.727)
and 1.239 (95% CI 1.001–2.082), respectively]. Consistent
with previous results, Mg levels were also negatively
correlated with PTH (P = 0.0001), c-term FGF23 (P =
0.0001), Ca levels (P = 0.026) and HOMA-IR (P = 0.003)
as well.
A growing body of evidence is supporting a cardinal role
of Mg in several diseases linked to vascular ageing in CKD-
MBD and diabetes. More speciﬁcally, low Mg levels were
associated with low insulin resistance, poor endothelial
reactivity, higher oxidative stress, increased intima-media
thickness, vascular calciﬁcation, progression of CKD and
mortality [6–9]. Although the common clinical experience
depicted how Mg was directly involved in the altered Ca
and PTH homeostasis, as in those cases of symptomatic
hypocalcaemia secondary to severe hypomagnesaemia
[10], the speciﬁc hormonal regulation of Mg balance and
the speciﬁc pathways linking Mg to the pathophysiology of
the mineral and vascular systems are still incompletely
understood. Of note, altered Mg levels were associated
with diabetes [7], menopause [11] and CKD [8], three con-
ditions that share a common phenotype of accelerated
vascular ageing, characterized by Monckeberg calciﬁca-
tion and impaired bone metabolism (ranging from ady-
namic bone disease in diabetes to high bone turnover in
osteoporotic menopausal women and certain CKD
patients). Nevertheless, the maintenance of adequate
intracellular Mg levels appears essential for life per se,
considering that Mg is a fundamental co-enzyme of vital
biochemical reactions as Krebs cycle and glycolysis [7]
and it is essential for the maintenance of RNA and DNA
stability [12]. Thus Mg may represent a cardinal biomarker
and regulator of vascular ageing in humans, with special
emphasis in CKD diabetic patients. Furthermore, nephrolo-
gists are called to a growing comprehension of Mg physi-
ology, as a consequence of the renewed adoption of Mg as
a P binder, now available in a single formulation together
with calcium-acetate [13].
The data by Fragoso et al. [5] conﬁrm the growing inter-
est that nephrology community should point towards Mg
metabolism with particular emphasis on CKD-MBD dia-
betic patients.
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Magnesium balance in healthy and renal patients
Magnesium is an important element for several physio-
logic processes in humans, as the maintenance of bone
health and the well functioning of the nervous system,
energy metabolism and the synthesis of proteins, DNA
and RNA [14]. The Mg storage in healthy adults amounts
to 25 g (2000 mEq), 99% of whom are intracellularly dis-
tributed. As intracellular cation, Mg is mainly stored at the
bone level (60–65%) and to a lesser extent into skeletal
muscles (25–30%) and in other soft tissues (10–15%).
Only 5–10% of the intracellular Mg is free, while the re-
maining is bound to proteins, citrates, RNA and DNA. Con-
sequently, circulating Mg represents only 1% of the total
body contents, ranging between 0.62 and 1.02 mmol/L,
where the 60% of this circulates as the biologically active
free cation, while the remaining 40% is protein bound or
complexed as salts. A neutral balance of Mg requires a
daily intake of 0.5–0.7 mEq/Kq of Mg, which is mainly
present in cereals, nuts, legumes and green vegetables.
Ingested Mg is thereafter absorbed in the proximal portion
of the small intestine via a paracellular route and to a
lesser extent in the colon via transcellular transport, prob-
ably involving the epithelial transient receptor potential
melastin 6 (TRPM6) [15]. The rate of magnesium absorp-
tion ranges from 25 to 80%, accordingly to different nutri-
tional intakes [14]. In normal subjects, the kidneys ﬁlter
∼70–80% of the plasmatic Mg, 95% of which are reab-
sorbed, mainly in the thick ascending limb of the loop of
Henle (TAL) [15]. In the proximal tubule and in the TAL Mg
is reabsorbed together with Ca via a passive paracellular
transport mediated by claudin-16 and claudin-19. Notably
Ca and Mg, as activators of the calcium sensing receptor
(CaSR), can reduce Mg excretion at this site via the lysoso-
mal degradation of claudin-16. On the opposite, the reab-
sorption of Mg and Ca in the distal convoluted tubule
(DCT) is driven by active transcellular processes, via the
TRMP6 channel expressed in the ﬁrst segment of DCT
(DCT1) and via the transient receptor potential vanilloid 5
(TRPV5) in the late DCT (DCT2). Also at this site of the
nephron, CaSR seems to interact with Mg handling. A
crosstalk between CaSR and the potassium basolateral
channel Kir4.1 may inﬂuence the TRPM6 activity in the
DCT1, while the increased urinary Ca levels in TRPV5-null
mice downregulated the aquaporin 2 water channel via
the activation of the luminal CaSR, protecting from
calcium deposits [15].
Although a speciﬁc hormonal regulation of Mg balance
has not been clearly shown, several hormones and acid-
base balance seem involved in Mg handling. Insulin can
directly stimulate the renal Mg resorption, favouring the
translocation of TRPM6 in the cell surface of the DCT [16].
Oestrogens normalized the renal TRMP6 mRNA levels pre-
viously reduced by Mg restriction in mouse models [17].
Chronic metabolic acidosis decreased renal TRPM6
expression leading to hypermagnesuria, while an opposite
effect was induced by metabolic alkalosis [18]. Further-
more, moving from bench to bedside, Mg balance needs
to be cautiously interpreted considering the several con-
comitant treatments that may inﬂuence Mg excretion as
thiazide and loop diuretics, acetazolamide [18], proton
pump inhibitors [19], chemotherapies [20] and calcineurin
inhibitors [21].
The trend of Mg levels in CKD is still controversial. Until a
glomerular ﬁltration rate (GFR) higher than 30 mL/min Mg
levels are commonly maintained in the normal range.
Although the total pool of Mg can be increased along with
the further reduction of GFR, the ionic Mg is more com-
monly normal, due to Mg bound with phosphate and
other ions. Not severe hypermagnesaemia (<2 mmol/L) is
frequent and asymptomatic in dialysis patients. Notably,
the levels of Mg commonly assessed by the available
assays should be cautiously interpreted especially in CKD,
considering that circulating Mg represents the 1% of the
organic Mg pool and that ionized and intracellular Mg
levels could be more representative of the active Mg state
[7]. As it is speculated for the circulating P levels [3], the
signiﬁcant variation of the circulating Mg concentrations
could represent a late event in respect to faster and more
relevant variations of intracellular and skeletal Mg levels.
Actually, in the study by Fragoso et al. [5], higher circulat-
ing Mg levels, although within the normal range in CKD
patients, were associated with a signiﬁcant vascular
damage, represented by higher P. Thus, further investi-
gations on Mg pathophysiology could lead to a revaluation
of the ‘normal’ Mg levels or to a more appropriate Mg
assessment for clinical purposes in renal patients.
Magnesium and mineral metabolism
Although the skeletal system represents the principal Mg
store in humans, where it is concentrated into the
hydration shell surrounding hydroxyapatite crystals [14],
the relation of Mg with other skeletal ions (Ca and P) and
with the regulatory hormones of mineral metabolism
(PTH, Vitamin D, FGF23/Klotho) is still incompletely
understood.
Old studies observed that a high Mg content in the
bones was associated with osteomalacic mineralization
defects probably due to the interference with Ca solubility
or by the precipitation of Mg with pyrophosphate [14]. On
the contrary hypomagnesaemia was associated with
reduced bone mineral density [15]. The action of Mg on
PTH looks different in the presence of chronic-severe hypo-
magnesaemia and in the presence of normal-high Mg
levels. Chronic and severe Mg deﬁciency is classically
associated with severe hypocalcaemia secondary to im-
paired PTH secretion and to peripheral resistance to PTH
action [10]. In those cases, the administration of Mg
rapidly restored normal levels of calcium through the nor-
malization of PTH synthesis and action. On the opposite in
vitro and in vivo studies observed that high Mg concen-
trations inhibited PTH secretion. It is well known that mag-
nesium can inhibit PTH secretion via the direct activation
of CaSR, but this action seems limited in the presence of
low Ca levels [22]. Furthermore, the incubation of para-
thyroid gland with high Mg media induced the expression
of vitamin D receptor (VDR), Klotho and FGF23 receptor
[22]. Notably the reduction of PTH secretion at moderately
elevated Mg levels did not lead to a PTH over-suppression
[22]. Notably, low Mg levels and low Mg dietary intake was
associated with osteoporosis, a classic high bone turnover
condition [11]. Magnesium supplementation improved the
hormonal assets and the urinary markers of bone turnover
in osteoporotic postmenopausal women [11]. Magnesium
carbonate is now available as P binder in a unique formu-
lation with calcium acetate (CaMg). In the CALMAG study,
CaMg was comparable to sevelamer-hydrochloride (HCl)
in the control of P levels in dialysis patients [13]. Further-
more, CaMg reduced the FGF23 levels similarly to sevela-
mer-HCl [23], contrarily to the previous data reporting a
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lower reduction of FGF23 levels in normophosphatemic
CKD patients receiving Ca acetate compared with those
treated with sevelamer. The mechanisms linking CaMg P
binder to a more potent FGF23 suppression compared
with the calcium alone, P binders are still incompletely
understood.
It could be speculated that while severe hypomagne-
saemia leads to symptomatic relative hypoparathyroid-
ism, the maintenance of normal-high Mg levels could be
adjuvant in the control of secondary hyperparathyroidism
via the activation of CaSR and via the optimization of the
regulatory molecules acting on VDR and FGF23/Klotho
axis. Fragoso et al. [5], consistent with previous results, ob-
served that higher Mg levels were associated with a more
favourable mineral asset, characterized by lower PTH,
FGF23 and calcium levels. However, the cross-sectional
design limits any conclusion on a causal relation of Mg
with FGF23/Klotho and, more extensively, with mineral
metabolism, which still requires further investigation to be
clearly elucidated. Furthermore, whether Mg supplemen-
tation may improve bone health in CKD and osteoporotic
patients needs to be more extensively explored.
Magnesium: a possible link between glucose
metabolism and CKD-MBD?
Low Mg levels are an established risk factor for insulin
resistance, metabolic syndrome and diabetes [7]. How-
ever, recent insights support the role of Mg as relevant
trigger of insulin resistance rather than its mere bio-
marker. In fact, Mg deﬁciency can impair insulin sensitivity
via the direct inhibition of tyrosine kinase [7]. The conse-
quent insulin resistance and hyperglycaemia can increase
the urine Mg output through the downregulation of TRPM6
and hyperﬁltration [16]. Thus low Mg levels could be an
active sustainer of a vicious cycle contributing to the pro-
gressive worsening of insulin resistance towards diabetes.
Dietary Mg intake was associated with a higher risk of
metabolic syndrome and diabetes [7]. Conﬂicting results
have been reported about the potential beneﬁts of Mg
supplementation on glycaemic control. The meta-analysis
by Song et al. [24] observed that 4–16 weeks of sup-
plements with oral Mg, at a median dose of 360 mg/day,
was effective in reducing plasma fasting glucose levels,
however with no impact on glycated haemoglobin.
The results by Fragoso et al. [5] move in the same direc-
tion, showing a negative association between Mg and
insulin sensitivity assessed by HOMA-IR in diabetic CKD
patients. Notably, the association between HOMA-IR and
PP lost signiﬁcance in the multivariate analysis, where Mg
and FGF23 levels remained the only independent predic-
tors of PP. Thus, Mg metabolism could represent a con-
siderable link between glucose metabolism and vascular
ageing. Not surprisingly hypomagnesaemia was associ-
ated with several diabetic complications as retinopathy,
foot ulcerations and nephropathy. Low Mg levels resulted
an independent predictor of GFR decline in several studies
[8]. Furthermore, reduced Mg levels are considered impor-
tant inducers of vascular damage through several mech-
anisms, toghether with diabetes and CKD, as
inﬂammation, oxidative stress, vasoconstriction and hy-
pertension. Low Mg levels have been likewise associated
to the vascular damages common to diabetes and CKD,
as increased intima-media thickness, arterial stiffness and
vascular calciﬁcations (VC) [6].
Magnesium is a well-known P binder; thus, its dietary
administration in vivo, as well as its presence in the
culture media in vitro, can hamper the onset of P-induced
VC. However, recent insights have shown that Mg can
protect arterial walls from the P-induced VC also through
active processes. The in vitro study by Montezano et al.
[25], conducted on VSMC and aortas of rodents, observed
that Mg negatively regulated the osteogenic differen-
tiation of vascular smooth muscle cells (VSMC) through
the activity of transient receptor potential melastin
(TRPM7) and increased expression of protective proteins
as matrix-GLA protein, bone morphogenic protein 7 and
osteopontin. These results have been recently conﬁrmed
by Louvet et al. [26] in human VSMC in vitro. Surprisingly,
the protective action of Mg was hampered in dead cells
exposed to very high Mg concentrations, showing that the
protection of Mg requires an active cellular role to be ef-
fective. Nonetheless, Mg could be protective through the
direct activation of the CaSR in the VSMC and through the
downregulation of inﬂammatory and oxidative stressors.
Over the last decades a strict crosstalk between bones
and vascular system has been described. Alterations in
bone handling, from low to high bone turnover, appeared
both related to higher VC and worse survival in CKD. Dia-
betic patients are characteristically prone to osteopenia and
to low PTH levels [27], the latter probably due to a reduced
PTH secretion [28]. This relative hypoparathyroidism in dia-
betic ESRD patients was associated with an accelerated pro-
gression of VC [29]. Furthermore, a lower response of
diabetic patients to the phosphaturic action of the FGF23/
Klotho system after dietary P load has been reported [30].
In addition, it has been documented an impaired response
of FGF-23 to oral phosphate in patients with type 2 diabetes,
a possible mechanism of atherosclerosis, and poor renal
response to FGF23 were associated with a higher CVD and
mortality risk in humans [31]. Thus, FGF23 resistance could
make diabetic patients even more susceptible to P overload
and to the consequent higher risk of VC. Furthermore, lower
FGF23 levels were associated with higher HOMA-IR as well
[32]. Low Mg content in bones has been repeatedly reported
in diabetic rats where it was reversible through the adminis-
tration of Mg [33] and insulin [34]. Even more, Mg sup-
plementation restored PTH levels in diabetic patients
probably correcting the altered PTH secretion [27].
Data by Fragoso et al. [5], highlighting Mg and FGF23 as
two independent predictors of arterial stiffness in CKD
diabetic patients, are consistent with the evidence men-
tioned above. Thus, it can be argued that hypomagnesae-
mia or, even more strikingly, the reduced levels of
intracellular Mg may be actively detrimental for CKD-MBD
in diabetes, contributing to low bone turnover, renal
FGF23 resistance, poor insulin sensitivity and lower protec-
tion against inﬂammation and oxidative stress in arteries
leading to higher VC. Whether Mg supplementation could
improve CKD-MBD in diabetic patients still needs to be in-
vestigated. Furthermore, our considerations are far from
encourageing the maintenance of a marked hypermagne-
saemia in renal patients, which could be toxic [14] and
associated to a higher all-cause mortality probably also
through relative hypoparathyroidism [9].
Conclusions
The study by Fragoso et al. [5] represents a relevant step
forward in our epidemiological knowledge about the
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important roles played by Mg and FGF23 in the arena of
vascular ageing in diabetes and CKD-MBD. However,
further investigations are required to better elucidate
whether Mg supplementation could improve vascular
ageing in diabetic CKD patients and to identify the
optimal circulating Mg levels in this particular population.
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